毒素A型治疗对患有红色素的患者的临床和生物物理参数的影响:一项前性,随机化,受控,双盲研究
Buğra Burç Dağtaş1, Ozan Erdem2, Tuğba İlter Güneç1
1Department of Dermatology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey.
概括
皮内肉毒素-A (BoNT-A) 显著降低了面部发红和可见的血管在患有红血斑管切开性粉红病 (ETR) 的患者. 这种治疗耐受性很好,为ETR管理提供了一个有前途的选择.
科学领域:
- 皮肤病学 皮肤病学
- 医学美学 医学美学
背景情况:
- 红发性白血病 (ETR) 呈现了治疗挑战,没有确立的黄金标准治疗.
- 新兴研究表明,皮肤内注射的毒素-A (BoNT-A) 可能对与ETR相关的红血症有效,但可靠的数据很少.
研究的目的:
- 评估皮肤内BoNT-A治疗ETR的疗效和耐受性.
- 提供关于BoNT-A对ETR症状的影响的客观数据.
主要方法:
- 一个随机,双盲,分脸试验,涉及30名ETR患者.
- 脸部的一侧接受了15个单位的皮内BoNT-A;另一个接受了盐水安慰剂.
- 评估包括临床医生的红斑评估 (CEA),患者自我评估 (PSA),墨西哥米读数 (红斑指数),皮肤镜检查和视频毛囊镜检查 (调查性全球评估 - IGA).
主要成果:
- 接受BoNT-A治疗的一方显示CEA得分,红斑指数和背景红斑显著下降.
- 视频毛囊显微镜显示了BoNT-A侧血管结构和密度 (IGA) 的显著改善.
- 患者报告结果 (PSA) 双边改善;没有发现严重不良事件.
结论:
- 皮内BoNT-A是一种有效且耐受良好的治疗方法,用于减少ETR中的红血和血管性.
- 这项研究支持BoNT-A作为ETR管理的可行治疗选择.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
653
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
653
Skeletal Muscle Relaxants: Therapeutic Uses
463
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
463
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
614
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
614
Skeletal Muscle Relaxants: Adverse Effects
335
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
335
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Local Anesthetics: Pharmacokinetics
729
The potency and duration of action of local anesthetics (LAs) are determined by their pharmacokinetics. Pharmacokinetics describes how LAs are absorbed, distributed, metabolized, and eliminated from the body. When administered to the vascular tissues, LAs are quickly absorbed and enter the systemic circulation, reducing their localized effects. Adding vasoconstrictors such as epinephrine to LAs reduces their absorption into the systemic circulation, making them clinically effective. The...
729


